Umoja Biopharma wins FDA IND clearance for first CD22-directed in vivo CAR-T therapy
Umoja Biopharma, a clinical-stage biotechnology company, announced on 21 July 2026 that the FDA has cleared its Investigational New Drug (IND) application for UB-VV400, a CD22-directed in vivo CAR-T cell therapy candidate. The company describes it as the industry's first known in vivo CAR-T programme targeting CD22 for relapsed or refractory B-cell malignancies.
UB-VV400 is built on Umoja's VivoVec lentiviral platform, which engineers CAR-T cells directly inside the patient's body — avoiding the ex vivo cell manufacturing, lymphodepletion and complex logistics that constrain conventional CAR-T therapies. The IND clearance allows Umoja to begin first-in-human clinical evaluation of the candidate.